WSWilliam K. Slover

William K. Slover

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William K. Slover has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Micro- and Nanoplastics and Liver Disease: Mechanistic Insights, Experimental Evidence, and Pathways to Hepatic Inflammation, Fibrosis, and Carcinogenesis

    by Priyata Dutta, Nicholas B. D’Alessandro, Tarun Vippa, William K. Slover, Kevin Houston, Edward C. Oldfield, David A. Johnson

    Micro–nanoplastics (MNPs) have emerged as a critical environmental pollutant with significant potential implications for the development of liver disease. These MNPs can accumulate in the liver, initiating a series of detrimental biological responses. One of the main mechanisms is the initiation of oxidative stress, which is marked by overproduction of reactive oxygen species harming cellular structures. This oxidative damage is closely linked to hepatic inflammation, where immune responses are triggered, exacerbating tissue injury and disrupting normal liver function. As a result, hepatic metabolism, detoxification, and immune regulation become compromised due to persistent MNPs exposure. Although in vitro and vivo models effectively show direct cellular toxicity, oxidative stress, and metabolic disruption, direct evidence from human studies is mostly confined to tissue detection and cross-sectional correlations. As a result, advanced pathological outcomes like the progression of hepatic fibrosis and the development of cancer are considered mechanistic hypotheses grounded in biological plausibility rather than confirmed human causation.

  • Open Access

    Potential Links Between Micro- and Nanoplastic Exposure, Enteric Neuropathy, and Gastrointestinal Dysmotility

    by William K. Slover, Nicholas B. D’Alessandro, Priyata Dutta, Tarun Vippa, Steve M. D’Souza, Edward C. Oldfield, David A. Johnson

    Micro- and nanoplastics (MNPs) have emerged as ubiquitous environmental contaminants, with dietary ingestion serving as the primary route of human exposure. While their capacity to induce localized epithelial damage is well recognized, recent evidence suggests that MNPs can alter the complex regulatory networks governing gastrointestinal (GI) transit. The objective of this narrative review is to evaluate the role of MNP exposure as a possible pathogenic factor in GI dysmotility, assessing the intersection of neuromuscular toxicity, microbial dysbiosis, and barrier failure. A comprehensive literature search was conducted across major biomedical databases to synthesize emerging biomonitoring studies, preclinical models, and clinical correlations from the past five years characterizing MNP-mediated intestinal dysfunction. Ingestion of MNPs triggers a distinct, size-dependent, multifaceted, interconnected pathological triad characterized by ensuing oxidative stress, physical barrier dysfunction, and extensive microbiome reconfiguration. Rather than strict, isolated events, these insults interact in a self-perpetuating feedback loop. On a cellular level, nano-sized particles translocate across the intestinal lining via paracellular transport, persorption, or transcytosis, embedding into cell membranes and downregulating key tight junction (TJ) proteins (ZO-1, occludin, claudins). This mechanical and chemical disruption yields an overproduction of reactive oxygen species (ROS) and a concomitant reduction in anti-inflammatory, short-chain fatty acid (SCFA)-producing bacterial taxa (e.g., Bacteroidetes, Faecalibacterium, Roseburia). Crucially, this resulting mucosal disruption converges on the enteric nervous system (ENS). MNPs induce neuroendocrine derangements by perturbing cholinergic neurotransmission—characterized by acetylcholinesterase (AChE) inhibition, aberrant synaptic acetylcholine dynamics, and subsequent downregulation of muscarinic acetylcholine receptors (mAChRs)—ultimately resulting in uncoordinated smooth muscle contractility and delayed transit. In murine models, this enteric neuropathy manifests phenotypically as structural intestinal shortening, delayed gastric emptying, and chronic constipation. The intestinal defense network is susceptible to MNP bioaccumulation, wherein particle-induced barrier failure and microbial dysbiosis may contribute to downstream neuromuscular dysmotility. Understanding this interconnected oxidative-barrier–microbiome–neuromuscular axis is essential, positioning environmental plastic contamination as an emerging, potentially modifiable factor in the pathogenesis of functional bowel disorders.